AGRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adecoagro SA (AGRO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock has already appreciated significantly year-to-date, and recent downgrades by analysts suggest limited upside potential in the near term. Additionally, the company's financial performance has been weak, with significant YoY declines in revenue, net income, and EPS. While there are some positive catalysts like the Profertil acquisition and higher urea prices, these appear to be largely priced into the stock. Given the lack of strong technical or proprietary trading signals, it is better to hold off on buying this stock for now.
The MACD is negatively expanding (-0.35), indicating bearish momentum. RSI is neutral at 30.721, and moving averages are converging, suggesting indecision. The stock is trading near its key support level of 13.111, with resistance at 15.421. Overall, the technical indicators do not suggest a strong buy signal.
The Profertil acquisition and higher urea prices are expected to drive future EBITDA and cash flow. Analysts have raised price targets in the past due to these factors. Additionally, the stock has performed well year-to-date, up 83%.
Recent analyst downgrades from Citi and BTG Pactual to Neutral suggest limited upside potential. The stock's valuation appears unattractive after its significant rally. Weak financial performance in Q3 2025, with revenue, net income, and EPS all declining sharply YoY, is a concern.
In Q3 2025, revenue dropped 35.48% YoY to $304.2M, net income dropped 65.81% YoY to $6.52M, and EPS turned negative at -$0.08, down 142.11% YoY. Gross margin also declined to 17.46%, down 25.48% YoY, indicating deteriorating profitability.
Analysts are mixed but leaning negative in the short term. Citi and BTG Pactual downgraded the stock to Neutral, citing unattractive valuations and limited upside after the recent rally. UBS and Morgan Stanley remain optimistic about the long-term impact of the Profertil acquisition and higher urea prices, but these factors appear to be priced in.
